Evidence‑Based Mechanisms
Minimally Invasive
Sjögren’s syndrome glandular inflammation visualization

Sjögren’s Syndrome

Immune Modulation Supportive Framework

Adjunctive regenerative approach for Sjögren’s syndrome using umbilical cord mesenchymal stem cells as core therapy, integrated with physical medicine and nutritional support. Minimally invasive techniques. No claim of cure – objective, verifiable information based on cell dynamic mechanisms.

Adjunctive
Status
1‑2
Treatment Sessions
Ongoing
Conventional Care
Adjunctive
Approach

Clinical Rationale

Umbilical cord mesenchymal stem cells exert immunomodulatory effects and secrete paracrine factors that regulate aberrant T‑cell and B‑cell activity, reducing pro‑inflammatory cytokines (TNF‑α, IL‑6, IFN‑γ, IL‑17) and lymphocytic infiltration involved in Sjögren’s syndrome pathogenesis. The supportive framework is strictly adjunctive; conventional rheumatologic care (hydroxychloroquine, immunosuppressants, symptomatic therapy) remains mandatory. Physical therapy addresses arthralgia and fatigue; nutritional medicine focuses on anti‑inflammatory patterns and hydration support. All techniques are minimally invasive (intravenous infusion or targeted microinjections). Peer‑reviewed investigations emphasize safety and mechanistic outcomes.

Mesenchymal stem cells in Sjögren’s syndrome: mechanisms & clinical evidence (NIH)
Immunomodulatory properties of MSCs in autoimmune exocrinopathy – systematic review

Supportive Components

Umbilical cord MSC
Physical therapy
Nutritional medicine
Minimally invasive
Immunomodulation
Adjunctive only
Meet Our Doctors Schedule Consultation

Comprehensive candidacy review

telemedicine or in‑person consultation

Best candidates & eligibility

This supportive approach is appropriate for a defined patient subset. Objective criteria:

  • Confirmed diagnosis of primary Sjögren’s syndrome (ACR/EULAR criteria)
  • Moderate to severe sicca symptoms or extraglandular involvement (ESSDAI ≥5)
  • Inadequate response or intolerance to conventional sicca or systemic therapies
  • No active malignancy or untreated infection
  • Age 18–75, no pregnancy/lactation
  • Willing to maintain concomitant rheumatologic care

Full eligibility determined via multidisciplinary intake and review of medical records. Not a replacement for first‑line treatment.

Individual results vary depending on lifestyle and underlying conditions.

Current Research and Clinical Evidence on MSCs in Sjögren’s Syndrome

Over the past decade, mesenchymal stem cells have been extensively investigated for their immunomodulatory properties in autoimmune diseases, including Sjögren’s syndrome. Multiple preclinical and clinical studies have explored the mechanisms, safety, and potential clinical benefits of MSC therapy in this context.

Preclinical Studies

Animal models, particularly non-obese diabetic (NOD) mice, have demonstrated that administration of MSCs can reduce lymphocytic infiltration in salivary glands, decrease autoantibody levels, and improve salivary flow rates. A notable study by Khalili et al. (2015) reported that adipose‑derived MSCs suppressed Th17 responses and promoted Treg expansion in NOD mice, attenuating sialadenitis.

Clinical Trials

Several phase I/II clinical trials have evaluated the safety and potential efficacy of MSC therapy in patients with primary Sjögren’s syndrome. A landmark study by Xu et al. (2012) reported that intravenous infusion of allogeneic MSCs was safe and resulted in significant improvements in visual analog scale for dryness, Schirmer’s test, and unstimulated salivary flow at 6‑month follow‑up.

Another study by Alunno et al. (2015) observed a shift in Treg/Th17 balance and a decrease in disease activity scores (ESSDAI) after MSC treatment. More recently, a phase I trial by Liang et al. (2022) confirmed the safety profile and noted sustained improvements in glandular function over 12 months.

Systematic Reviews and Meta‑Analyses

A comprehensive systematic review by Shi et al. (2020) analyzed 8 studies and concluded that MSC therapy appears to be safe and may provide some clinical benefits in Sjögren’s syndrome, but emphasized the need for larger, randomized controlled trials to confirm efficacy.

Proposed Mechanisms

MSCs exert their effects primarily through paracrine signaling, secreting anti‑inflammatory cytokines (IL‑10, TGF‑β), growth factors (HGF, EGF), and exosomes that modulate immune cell function. They promote regulatory T cells, inhibit Th17 differentiation, reduce B‑cell hyperactivity, and shift macrophage polarization toward an M2 phenotype. These combined actions help restore immune homeostasis in the exocrine gland microenvironment.

Limitations and Future Directions

Despite promising results, MSC therapy for Sjögren’s syndrome remains experimental. Current evidence is limited by small sample sizes, short follow‑up periods, heterogeneity in cell sources and protocols, and lack of standardized outcome measures. Regulatory approval for this indication is not yet granted in any country. Ongoing and future trials aim to address these gaps and establish more definitive evidence.

References: Xu J, et al. (2012) PMID: 22773394; Alunno A, et al. (2015) PMID: 26077406; Khalili S, et al. (2015) PMID: 26143058; Shi J, et al. (2020) PMID: 32779034; Liang J, et al. (2022) PMID: 34933340.
All information is based on peer‑reviewed literature and does not constitute medical advice. Individual results vary.

Minimally invasive delivery techniques

Cellular administrations are performed using intravenous infusion or precise localized microinjections with fine‑gauge needles. No surgical incisions, no general anesthesia. Procedure time: approximately 30‑60 minutes. Patients resume normal activities within 24‑48 hours. This approach reduces mechanical trauma and supports cellular distribution to inflamed glandular tissues.

Verifiable technique – utilized in registered clinical studies (NCT identifiers available on request).

Minimally invasive administration

precision, patient comfort

MSC therapy for Sjögren’s syndrome is not approved by the U.S. FDA, Mexican COFEPRIS (for this indication), or any other regulatory agency. It is considered an adjunctive, supportive procedure.

Costs are discussed only after a consultation.

Review date: June 2026

Medically reviewed by Dr. Guillermo Quezada, MD – June 2026, regenerative medicine specialist

Clinical note: This adjunctive supportive approach is not a replacement for prescribed Sjögren’s syndrome treatments (hydroxychloroquine, immunosuppressants, symptomatic therapies, etc.). Patients must continue those treatments under the direction of their prescribing rheumatologist.

Clinical guidance & insight: All candidates receive a comprehensive medical evaluation by a licensed physician. The supportive framework described here is based on current mechanistic understanding; individual response varies. Always consult your rheumatologist before modifying any treatment.